$EBS
Emergent BioSolutions Inc. Stock $ebs

$ebs Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000136764423000046 Filed on March 01, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$165.1M	$330.7M	$1.121B
YoY Change	-46.31%	-54.27%	-37.47%
Cost Of Revenue	$155.1M	$219.4M	$693.7M
YoY Change	-0.51%	3.05%	-3.11%
Gross Profit	$3.500M	$111.3M	$385.8M
YoY Change	-97.54%	-78.19%	-64.17%
Gross Profit Margin	2.12%	33.66%	34.42%
Selling, General & Admin	$100.5M	$94.20M	$340.3M
YoY Change	18.51%	0.0%	-2.32%
% of Gross Profit	2871.43%	84.64%	88.21%
Research & Development	$40.60M	$57.60M	$193.0M
YoY Change	-12.5%	-30.6%	-17.52%
% of Gross Profit	1160.0%	51.75%	50.03%
Depreciation & Amortization	$34.60M	$35.60M	$83.40M
YoY Change	11.97%	21.92%	34.08%
% of Gross Profit	988.57%	31.99%	21.62%
Operating Expenses	$141.1M	$169.7M	$533.3M
YoY Change	7.55%	-11.24%	-8.43%
Operating Profit	-$148.1M	-$58.40M	-$172.7M
YoY Change	-2414.06%	-118.3%	-148.98%
Interest Expense	$17.90M	-$12.80M	$37.30M
YoY Change	118.29%	42.22%	8.12%
% of Operating Profit
Other Income/Expense, Net	-$13.00M	$6.700M	-$49.00M
YoY Change	27.45%	-844.44%	28.27%
Pretax Income	-$161.1M	-$71.20M	-$221.7M
YoY Change	4139.47%	-126.62%	-170.52%
Income Tax	$21.90M	$16.80M	$2.100M
% Of Pretax Income
Net Earnings	-$183.0M	-$88.00M	-$223.8M
YoY Change	4845.95%	-146.49%	-196.93%
Net Earnings / Revenue	-110.84%	-26.61%	-19.97%
Basic Earnings Per Share	-$3.65		-$4.47
Diluted Earnings Per Share	-$3.65	-$1.77	-$4.47
COMMON SHARES
Basic Shares Outstanding	50.14M shares	49.89M shares	50.10M shares
Diluted Shares Outstanding	50.20M shares		50.10M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$430.2M	$642.6M	$642.6M
YoY Change	-1.28%	11.54%	11.54%
Cash & Equivalents	$430.2M	$642.6M	$642.6M
Short-Term Investments
Other Short-Term Assets	$267.3M	$57.90M	$57.90M
YoY Change	225.98%	-17.87%	-17.87%
Inventory	$367.9M	$351.8M	$351.8M
Prepaid Expenses
Receivables	$155.9M	$158.4M	$158.4M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.221B	$1.211B	$1.211B
YoY Change	11.0%	-4.83%	-4.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$716.8M	$817.6M	$837.0M
YoY Change	-11.23%	2.19%	1.04%
Goodwill	$218.2M	$218.2M
YoY Change	-2.98%	-2.98%
Intangibles	$608.9M	$728.8M
YoY Change	3.1%	20.54%
Long-Term Investments
YoY Change
Other Assets	$184.6M	$191.3M	$171.9M
YoY Change	223.29%	233.86%	492.76%
Total Long-Term Assets	$1.729B	$1.956B	$1.956B
YoY Change	2.88%	15.95%	15.95%
TOTAL ASSETS
Total Short-Term Assets	$1.221B	$1.211B	$1.211B
Total Long-Term Assets	$1.729B	$1.956B	$1.956B
Total Assets	$2.950B	$3.167B	$3.167B
YoY Change	6.09%	7.02%	7.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$124.2M	$103.5M	$103.5M
YoY Change	15.75%	-19.71%	-19.71%
Accrued Expenses	$21.30M	$34.90M	$129.0M
YoY Change	-27.3%	-32.5%	-11.76%
Deferred Revenue	$12.80M	$26.40M
YoY Change	28.0%	125.64%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$950.7M	$957.3M	$957.3M
YoY Change	2908.54%	2929.43%	2929.43%
Total Short-Term Liabilities	$1.216B	$1.230B	$1.230B
YoY Change	387.84%	229.03%	229.03%
LONG-TERM LIABILITIES
Long-Term Debt	$447.7M	$448.5M	$448.5M
YoY Change	-44.14%	-44.59%	-44.59%
Other Long-Term Liabilities	$24.10M	$33.40M	$33.40M
YoY Change	-51.12%	-46.04%	-46.04%
Total Long-Term Liabilities	$471.8M	$481.9M	$481.9M
YoY Change	-44.55%	-44.69%	-44.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.216B	$1.230B	$1.230B
Total Long-Term Liabilities	$471.8M	$481.9M	$481.9M
Total Liabilities	$1.747B	$1.784B	$1.784B
YoY Change	44.98%	33.1%	33.1%
SHAREHOLDERS EQUITY
Retained Earnings	$551.0M	$734.0M
YoY Change	-42.25%	-23.37%
Common Stock	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$227.7M	$227.7M
YoY Change	11.4%	49.61%
Treasury Stock Shares		5.600M shares
Shareholders Equity	$1.203B	$1.383B	$1.383B
YoY Change
Total Liabilities & Shareholders Equity	$2.950B	$3.167B	$3.167B
YoY Change	6.09%	7.02%	7.02%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$183.0M	-$88.00M	-$223.8M
YoY Change	4845.95%	-146.49%	-196.93%
Depreciation, Depletion And Amortization	$34.60M	$35.60M	$83.40M
YoY Change	11.97%	21.92%	34.08%
Cash From Operating Activities	-$184.0M	$92.80M	-$34.10M
YoY Change	393.3%	-71.79%	-110.62%
INVESTING ACTIVITIES
Capital Expenditures	$15.10M	$23.60M	$115.8M
YoY Change	-53.11%	-150.54%	-48.53%
Acquisitions
YoY Change
Other Investing Activities		-$21.80M	-$21.80M
YoY Change
Cash From Investing Activities	-$15.10M	-$45.40M	-$381.3M
YoY Change	-53.11%	-2.78%	69.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$82.10M
YoY Change			-22.55%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$10.50M	353.1M	$481.2M
YoY Change	-85.11%	-421.0%	-441.28%
NET CHANGE
Cash From Operating Activities	-$184.0M	92.80M	-$34.10M
Cash From Investing Activities	-$15.10M	-45.40M	-$381.3M
Cash From Financing Activities	-$10.50M	353.1M	$481.2M
Net Change In Cash	-$209.8M	400.5M	$66.30M
YoY Change	49.54%	132.44%	-246.68%
FREE CASH FLOW
Cash From Operating Activities	-$184.0M	$92.80M	-$34.10M
Capital Expenditures	$15.10M	$23.60M	$115.8M
Free Cash Flow	-$199.1M	$69.20M	-$149.9M
YoY Change	186.47%	-81.58%	-255.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001367644
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Derivative Asset Statement Of Financial Position Extensible Enumeration DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent
CY2021Q4	us-gaap	Derivative Asset Statement Of Financial Position Extensible Enumeration DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent
CY2022Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense
CY2022	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense
CY2020Q3	ebs	Debt Instrument Covenant Net Leverage Ratio Adjustment Period DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod	P12M
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-33137
CY2022	dei	Entity Registrant Name EntityRegistrantName	EMERGENT BIOSOLUTIONS INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	14-1902018
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Professional Drive, Suite 400
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg,
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20879
CY2022	dei	City Area Code CityAreaCode	240
CY2022	dei	Local Phone Number LocalPhoneNumber	631-3200
CY2022	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	EBS
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1500000000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	70300000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50140158	shares
CY2022Q4	us-gaap	Goodwill Goodwill	218200000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	6700000	usd
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Tysons, Virginia
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	642600000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	576100000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	158400000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	274700000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	351800000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	350800000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	57900000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1210700000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1272100000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	817600000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	800100000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	728800000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	604600000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	218200000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	224900000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	191300000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57300000	usd
CY2022Q4	us-gaap	Assets Assets	3166600000	usd
CY2021Q4	us-gaap	Assets Assets	2959000000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	103500000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	128900000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34900000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51700000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	88300000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	88700000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	957300000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	31600000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	45900000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	72900000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1229900000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	373800000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	448500000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	809400000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	71800000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	94900000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33400000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	61900000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1783600000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1340000000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000.0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000.0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000.0	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000.0	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55700000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55100000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50100000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51300000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	100000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	100000	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5600000	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3800000	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	227700000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	152200000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	873500000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	829400000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3100000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16100000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	734000000.0	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	957800000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1383000000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1619000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3166600000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2959000000	usd
CY2022	us-gaap	Revenues Revenues	1120900000	usd
CY2021	us-gaap	Revenues Revenues	1792700000	usd
CY2020	us-gaap	Revenues Revenues	1555400000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	193000000.0	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	234000000.0	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	234500000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	340300000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	348400000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	303300000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	6700000	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	41700000	usd
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	59900000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	58500000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	59800000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1293600000	usd
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1440100000	usd
CY2020	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1121600000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-172700000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	352600000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	433800000	usd
CY2022	us-gaap	Interest Expense InterestExpense	37300000	usd
CY2021	us-gaap	Interest Expense InterestExpense	34500000	usd
CY2020	us-gaap	Interest Expense InterestExpense	31300000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11700000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3700000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4700000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-49000000.0	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38200000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26600000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-221700000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	314400000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	407200000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2100000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83500000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	102100000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223800000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	230900000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	305100000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.47
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.32
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.79
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.47
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.27
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.67
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50100000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53500000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52700000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50100000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54100000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53800000	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223800000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	230900000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	305100000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1000000.0	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1000000.0	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1700000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	10700000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	6500000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-9400000	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-7500000	usd
CY2021	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-3700000	usd
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	4300000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19200000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9200000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15400000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-204600000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	240100000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	289700000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223800000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	230900000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	305100000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	45100000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	42400000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	51000000.0	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	143300000	usd
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	123800000	usd
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	114500000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2600000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2900000	usd
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	31700000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	4100000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	4100000	usd
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3500000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	6700000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	41700000	usd
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	29000000.0	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-19000000.0	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	46900000	usd
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2400000	usd
CY2022	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	usd
CY2021	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	17200000	usd
CY2020	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6400000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2000000.0	usd
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5200000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-114700000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	48200000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-49000000.0	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	51900000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	44000000.0	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	83200000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19900000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7700000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29200000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-14000000.0	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2500000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	18700000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-66700000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	141000000.0	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-9200000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	19400000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	100000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4000000.0	usd
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	21800000	usd
CY2022	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	28600000	usd
CY2021	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	-32400000	usd
CY2020	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	1100000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9600000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-31800000	usd
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	11200000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34100000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	321100000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	536000000.0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	115800000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	225000000.0	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	21800000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	0	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	0	usd
CY2020	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	10000000.0	usd
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	243700000	usd
CY2021	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0	usd
CY2020	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-381300000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-225000000.0	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-151000000.0	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	82100000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	106000000.0	usd
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	450000000.0	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	10600000	usd
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	598000000.0	usd
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2020	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	373000000.0	usd
CY2022	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	33800000	usd
CY2021	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	25300000	usd
CY2020	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	14100000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	5000000.0	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	15900000	usd
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	31600000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5900000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13800000	usd
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13800000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	8400000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1200000	usd
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	2800000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	481200000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-141000000.0	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	69500000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	500000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-300000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1000000.0	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	66300000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45200000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	453500000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	576300000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	621500000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168000000.0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	642600000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	576300000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	621500000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	33000000.0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	30400000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	21000000.0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	6200000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	71600000	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	109300000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9400000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	20000000.0	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	22000000.0	usd
CY2022	ebs	Noncash Purchases Of Treasury Stock NoncashPurchasesOfTreasuryStock	0	usd
CY2021	ebs	Noncash Purchases Of Treasury Stock NoncashPurchasesOfTreasuryStock	6600000	usd
CY2020	ebs	Noncash Purchases Of Treasury Stock NoncashPurchasesOfTreasuryStock	0	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	642600000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	576100000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	621300000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	usd
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	642600000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	576300000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	621500000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1088500000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	305100000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15400000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	68800000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1447000000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	230900000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9200000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	44500000	usd
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	112600000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1619000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223800000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19200000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	44100000	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	75500000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1383000000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Nature of the business and organization <div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organization and business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (“Emergent,” the “Company,” “we,” “us,” and “our”) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats ("PHTs"). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following five PHT categories: chemical, biological, radiological, nuclear and explosives ("CBRNE"); emerging infectious diseases ("EID"); travel health; emerging health crises; and acute/emergency care. The Company has a product portfolio of thirteen products (vaccines, therapeutics, and drug-device combination products). The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company has one product candidate that is procured under special circumstances by the United States government ("USG"), although it is not approved by the United States Food and Drug Administration ("FDA"). The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following three product and service categories: Government - Medical Countermeasures ("MCM") Products, Commercial Products, and CDMO Services. The Company operates as two operating segments: (1) a products segment ("Products") consisting of the Government - MCM and Commercial product categories and (2) a services segment ("Services") focused on CDMO services (Note 16, "Segment information</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Government - MCM Products</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.14pt">ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Anthrasil® (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.96pt">Anthrax vaccines, including our AV7909 (Anthrax vaccine adsorbed (AVA), adjuvanted) procured product candidate being developed as a next-generation anthrax vaccine for post-exposure prophylaxis and BioThrax® (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. AV7909 has not been approved by the FDA, but is procured by certain authorized government buyers for their use;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.14pt">BAT® (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">CNJ-016® (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Ebanga™ (ansuvimab-zykl) is a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics ("Ridgeback"). Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga™ in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga™;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">RSDL® (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA that is intended to remove or neutralize chemical warfare agents from the skin, including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">TEMBEXA®, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Trobigard® atropine sulfate, obidoxime chloride auto-injector, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It was approved in Belgium in 2021 but has not been approved by the FDA. Trobigard is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure outside of the U.S.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Commercial Products</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">NARCAN</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone approved by the FDA and Health Canada for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Vaxchora</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the first vaccine approved by the FDA for the prevention of cholera, which we have agreed to sell as part of our travel health business; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Vivotif</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), a live attenuated vaccine for oral administration for the prevention of typhoid fever, which we have agreed to sell as part of our travel health business.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services - Contract Development and Manufacturing </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's services line focused on CDMO offerings cover development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided across the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale. Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company acquired from Chimerix ("the Seller") the exclusive worldwide rights to brincidofovir, including TEMBEXA® and related assets (the “Transaction”). TEMBEXA is an oral antiviral medical countermeasure to treat smallpox approved by the FDA in June 2021. Under the terms of the Asset Purchase Agreement (the "Purchase Agreement"), the Company paid $238.0 million upon closing of the Transaction, and is subject to potential milestone payments of up to $124.0 million contingent on the potential exercise by the USG of procurement options. The closing payment and the milestone payments were based on the actual procurement value of the procurement contract (the "BARDA Contract") with the Biomedical Advanced Research and Development Authority (“BARDA”). Each milestone payment is associated with the exercise of future BARDA procurement options of TEMBEXA following the BARDA Contract base period. The Seller is also eligible to receive up to $12.5 million in regulatory milestones associated with the SymBio Pharmaceuticals Ltd. brincidofovir licensing arrangements assumed by the Company in the Transaction. The milestone payments will be recorded when the associated procurement options have been exercised and/or the regulatory milestones have been met and the consideration is paid or becomes payable. The total consideration paid in the Transaction was allocated based on the proportionate fair value of the assets acquired. We recorded $156.9 million in intangible assets, net and $82.3 million in inventories, net upon execution of the Transaction on our consolidate balance sheet.</span></div>The Seller may also earn a 20% royalty on future gross profit of TEMBEXA in the United States associated with volumes above 1.7 million treatment courses of therapy during the exclusivity period of TEMBEXA. Outside of the United States, the Purchase Agreement also allows the Seller to earn a 15% royalty on all gross profit associated with TEMBEXA sales during the exclusivity period of TEMBEXA on a market-to-market basis. Refer to Note 5 "Intangible assets and goodwill" for additional information around the impacts of this asset acquisition on the current period results.
CY2021	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	41500000	usd
CY2022	ebs	Number Of Categories Of Public Health Threats NumberOfCategoriesOfPublicHealthThreats	5	category
CY2022	ebs	Number Of Revenue Generating Products NumberOfRevenueGeneratingProducts	13	product
CY2022	ebs	Number Of Product Candidates NumberOfProductCandidates	1	productcandidate
CY2022	ebs	Number Of Product And Service Categories NumberOfProductAndServiceCategories	3
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	642600000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	The preparation of financial statements requires management to make estimates, judgments and assumptions that affect reported amounts and disclosures for asset impairments, revenue recognition, allowances for doubtful accounts, inventory, depreciation and amortization, business combinations, contingent consideration, stock-based compensation, income taxes, and other contingencies. Management continually re-evaluates its estimates, judgments and assumptions. These estimates are sometimes complex, sensitive to changes in assumptions and require fair value determinations using Level 3 fair value measurements. Actual results may differ materially from those estimates.
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Customers</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has long-term contracts with the USG that expire at various times from 2023 through 2036. The Company has derived a significant portion of its revenue from sales of our Government - MCM products under contracts with the USG. The Company's current USG contracts do not necessarily increase the likelihood that it will secure future comparable contracts with the USG. The Company expects that a significant portion of the business will continue to be under government contracts that present a number of risks that are not typically present in the commercial contracting process. USG contracts for ACAM2000 and Anthrax Vaccines and other medical countermeasures products are subject to unilateral termination or modification by the government. The Company may fail to achieve significant sales of its medical countermeasures products, including ACAM2000 and Anthrax Vaccines to customers in addition to the USG, which would harm their growth opportunities. The Company's other product sales, largely Nasal Naloxone Products, are largely sold commercially through physician-directed or standing order prescriptions at retail pharmacies, as well as to state health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. In 2022, we filed our supplemental New Drug Application for NARCAN® (naloxone HCI) Nasal Spray, as an over-the-counter emergency treatment which if approved would further broaden our customer base. Our CDMO customers are generally third-party pharmaceutical companies. Refer to Footnote 11, "Revenue recognition" for more information regarding significant customers. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company seeks to expand its customer base and to renew its agreements with its customers prior to expiration of a contract, a delay in securing a renewal or a failure to secure a renewal or securing a renewal on less favorable terms may have a material adverse effect on the Company’s financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable do not represent a significant concentration of credit risk. The USG accounted for approximately 43%, 50% and 64% of total revenues for 2022, 2021 and 2020, respectively. The Company’s accounts receivable as of December 31, 2022 and 2021, consist primarily of amounts due from the USG or other large multi-national highly reputable customers for product sales, CDMO services or from government agencies under government grants. Management does not deem credit risk to be significant.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financial Institutions</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are maintained with several financial institutions. The Company has deposits held with banks that exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions of reputable credit and, therefore, bear minimal credit risk.</span></div><div style="margin-bottom:5pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Lender Counterparties</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is lender counterparty risk associated with the Company's revolving credit facility and derivatives instruments. There is risk that the Company’s revolving credit facility investors and derivative counterparties will not be available to fund as obligated. If funding under the revolving credit facility is unavailable, the Company may have to acquire a replacement credit facility from different counterparties at a higher cost or may be unable to find a suitable replacement. The Company seeks to manage risks from its revolving credit facility and derivative instruments by contracting with experienced large </span></div>financial institutions and monitoring the credit quality of its lenders. As of December 31, 2022, the Company does not anticipate nonperformance by any of its counterparties.
CY2022Q4	ebs	Number Of Stock Based Employee Compensation Plans NumberOfStockBasedEmployeeCompensationPlans	1	plan
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P7Y
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	143400000	usd
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	217500000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	116200000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	95800000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	92200000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	37500000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	351800000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	350800000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1201400000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1119200000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	383800000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	319100000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	817600000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	800100000	usd
CY2022	us-gaap	Depreciation Depreciation	83400000	usd
CY2021	us-gaap	Depreciation Depreciation	62200000	usd
CY2020	us-gaap	Depreciation Depreciation	50100000	usd
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P14Y4M24D
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1016200000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	287400000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	728800000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	832100000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	227500000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	604600000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	21800000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	59900000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	58500000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	59800000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	71500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	71500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	71500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	70200000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	67000000.0	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	377100000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	728800000	usd
CY2020Q4	us-gaap	Goodwill Goodwill	266700000	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	41700000	usd
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-100000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	224900000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	6700000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	0	usd
CY2022Q4	us-gaap	Goodwill Goodwill	218200000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	6700000	usd
CY2022Q4	us-gaap	Derivative Assets DerivativeAssets	8500000	usd
CY2021Q4	us-gaap	Derivative Assets DerivativeAssets	0	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	500000000.0	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	352400000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	6800000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	37200000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	6100000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	32700000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6800000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	43300000	usd
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	29200000	usd
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	31700000	usd
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	2800000	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	58100000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2900000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	23800000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	37200000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2600000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	33000000.0	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	6800000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	3100000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	1413800000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	849600000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	957300000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	31600000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	8000000.0	usd
CY2021Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	8500000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	448500000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	809400000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	1300000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	2000000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1600000	usd
CY2020Q3	ebs	Debt Instrument Covenant Net Leverage Ratio Rolling Period DebtInstrumentCovenantNetLeverageRatioRollingPeriod	P12M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	15700000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	961500000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	300000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2000000.0	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	450000000.0	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	1413800000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022	ebs	Common Stock Number Of Votes Per Common Share CommonStockNumberOfVotesPerCommonShare	1	vote
CY2021Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	250000000	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	187900000	usd
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	4400000	shares
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1800000	shares
CY2021	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2600000	shares
CY2022	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	42.36
CY2021	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	42.67
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	75500000	usd
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	112600000	usd
CY2022Q4	ebs	Number Of Stock Based Employee Compensation Plans NumberOfStockBasedEmployeeCompensationPlans	1	plan
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y3M18D
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	500000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10400000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27600000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	17.85
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	35.16
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	21.69
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	38200000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	12000000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45100000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42400000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	51000000.0	usd
CY2021	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	4000000.0	usd
CY2021	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-5200000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9200000	usd
CY2022	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	20500000	usd
CY2022	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	1300000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19200000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	23900000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	4700000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19200000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	12000000.0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	2800000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9200000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-19800000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-4400000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15400000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223800000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223800000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	230900000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	305100000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50100000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53500000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52700000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	600000	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1100000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50100000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54100000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53800000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.47
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.32
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.79
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.47
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.27
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.67
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2800000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1000000.0	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022	us-gaap	Revenues Revenues	1120900000	usd
CY2021	us-gaap	Revenues Revenues	1792700000	usd
CY2020	us-gaap	Revenues Revenues	1555400000	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	4900000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	378200000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	378200000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P24M
CY2022Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	34800000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	21500000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	100100000	usd
CY2021	ebs	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	279700000	usd
CY2021	ebs	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	363400000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16400000	usd
CY2022	ebs	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	38900000	usd
CY2022	ebs	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	23600000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	31700000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	26400000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11700000	usd
CY2022Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	102700000	usd
CY2021Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	228100000	usd
CY2022Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	56400000	usd
CY2021Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	49800000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	700000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3200000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	158400000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	274700000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5600000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5600000	usd
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4500000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1100000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1300000	usd
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1100000	usd
CY2022	us-gaap	Lease Cost LeaseCost	6700000	usd
CY2021	us-gaap	Lease Cost LeaseCost	6900000	usd
CY2020	us-gaap	Lease Cost LeaseCost	5600000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19400000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	28300000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5800000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5800000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14800000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24200000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20600000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	30000000.0	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041
CY2022Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2022	ebs	Lessee Operating Lease Termination Period LesseeOperatingLeaseTerminationPeriod	P1Y
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6500000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4300000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2700000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2300000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1800000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	5900000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	23500000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2900000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20600000	usd
CY2022	ebs	Valuation Allowance Deferred Tax Asset Increase Decrease Including Cumulative Translation Adjustment Amount ValuationAllowanceDeferredTaxAssetIncreaseDecreaseIncludingCumulativeTranslationAdjustmentAmount	43800000	usd
CY2022Q4	ebs	Deferred Tax Liabilities Foreign Withholding Tax DeferredTaxLiabilitiesForeignWithholdingTax	4700000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-9600000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-3700000	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	62800000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000000.0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	14900000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	27700000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	33600000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	28400000	usd
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	14000000.0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	26000000.0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	39600000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	104500000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-39000000.0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	38000000.0	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1100000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	8200000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4300000	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	6900000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	1600000	usd
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3500000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-23900000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	43900000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2400000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2100000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83500000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	102100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	15300000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	7600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	5400000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	3300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	18400000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	16600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10100000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	9100000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	10200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2000000.0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	10500000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2900000	usd
CY2022Q4	ebs	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	4600000	usd
CY2021Q4	ebs	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	6500000	usd
CY2022Q4	ebs	Deferred Tax Assets Tax Deferred Expense Capitalized Costs DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts	5000000.0	usd
CY2021Q4	ebs	Deferred Tax Assets Tax Deferred Expense Capitalized Costs DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts	3900000	usd
CY2022Q4	ebs	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	25900000	usd
CY2021Q4	ebs	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	7600000	usd
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	700000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	114600000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	65900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	68000000.0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25000000.0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	46600000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	40900000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	62400000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	75100000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	46100000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	47600000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	4300000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	6100000	usd
CY2022Q4	ebs	Deferred Tax Liabilities Foreign Withholding Tax DeferredTaxLiabilitiesForeignWithholdingTax	4700000	usd
CY2021Q4	ebs	Deferred Tax Liabilities Foreign Withholding Tax DeferredTaxLiabilitiesForeignWithholdingTax	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	900000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2800000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	118400000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	131600000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	71800000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	90700000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	43000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-445100000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	112000000.0	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	362000000.0	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	223400000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	202400000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	45200000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-221700000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	314400000	usd
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	407200000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-46600000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	65800000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	85500000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-10200000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	16100000	usd
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	23200000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-7000000.0	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-16800000	usd
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-7800000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	43800000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4300000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1500000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	3500000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	4700000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	7600000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	4700000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-4900000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-7900000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	1800000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	8300000	usd
CY2020	us-gaap	Pension Expense PensionExpense	2400000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-500000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	800000	usd
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-700000	usd
CY2022	ebs	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	0	usd
CY2021	ebs	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	300000	usd
CY2020	ebs	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	6000000.0	usd
CY2022	ebs	Effective Income Tax Rate Reconciliation Compensation Limitation Amount EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount	700000	usd
CY2021	ebs	Effective Income Tax Rate Reconciliation Compensation Limitation Amount EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount	2900000	usd
CY2020	ebs	Effective Income Tax Rate Reconciliation Compensation Limitation Amount EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount	2200000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-9700000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	300000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-300000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	20700000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	11400000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	5400000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9800000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9200000	usd
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	10400000	usd
CY2022	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	4700000	usd
CY2021	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	0	usd
CY2020	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	0	usd
CY2022	ebs	Effective Income Tax Rate Reconciliation Permanent Difference EffectiveIncomeTaxRateReconciliationPermanentDifference	-3200000	usd
CY2021	ebs	Effective Income Tax Rate Reconciliation Permanent Difference EffectiveIncomeTaxRateReconciliationPermanentDifference	300000	usd
CY2020	ebs	Effective Income Tax Rate Reconciliation Permanent Difference EffectiveIncomeTaxRateReconciliationPermanentDifference	-2600000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2100000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83500000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	102100000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.01
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.27
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.01
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.27
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25
CY2022Q4	ebs	Unrecognized Tax Benefits Noncurrent UnrecognizedTaxBenefitsNoncurrent	1200000	usd
CY2021Q4	ebs	Unrecognized Tax Benefits Noncurrent UnrecognizedTaxBenefitsNoncurrent	9800000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1500000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	400000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	900000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	200000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	600000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	1800000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	8000000.0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1200000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9800000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9200000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1200000	usd
CY2022	us-gaap	Pension Expense PensionExpense	800000	usd
CY2021	us-gaap	Pension Expense PensionExpense	2000000	usd
CY2021Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	29300000	usd
CY2020Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	27600000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1500000	usd
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1400000	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	900000	usd
CY2021	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	900000	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	3400000	usd
CY2021	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	500000	usd
CY2022	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	-400000	usd
CY2021	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	-100000	usd
CY2022	us-gaap	Defined Benefit Plan Settlements Plan Assets DefinedBenefitPlanSettlementsPlanAssets	5000000.0	usd
CY2021	us-gaap	Defined Benefit Plan Settlements Plan Assets DefinedBenefitPlanSettlementsPlanAssets	0	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	-400000	usd
CY2021	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	-1000000.0	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	29300000	usd
CY2021Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	29300000	usd
CY2021Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	46800000	usd
CY2020Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	49200000	usd
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	1900000	usd
CY2021	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2400000	usd
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	100000	usd
CY2021	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	0	usd
CY2022	us-gaap	Defined Benefit Plan Benefit Obligation Contributions By Plan Participant DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant	900000	usd
CY2021	us-gaap	Defined Benefit Plan Benefit Obligation Contributions By Plan Participant DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant	900000	usd
CY2022	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	10000000.0	usd
CY2021	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	4600000	usd
CY2022	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	3400000	usd
CY2021	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	500000	usd
CY2022	us-gaap	Defined Benefit Plan Settlements Benefit Obligation DefinedBenefitPlanSettlementsBenefitObligation	5000000.0	usd
CY2021	us-gaap	Defined Benefit Plan Settlements Benefit Obligation DefinedBenefitPlanSettlementsBenefitObligation	0	usd
CY2022	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	-900000	usd
CY2021	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	-1600000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	37200000	usd
CY2021Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	46800000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-7900000	usd
CY2021Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-17500000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses After Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax	34000000.0	usd
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses After Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax	41800000	usd
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	1900000	usd
CY2021	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2400000	usd
CY2020	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	1900000	usd
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	100000	usd
CY2021	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	0	usd
CY2020	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	100000	usd
CY2022	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	800000	usd
CY2021	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	800000	usd
CY2020	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	600000	usd
CY2022	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-100000	usd
CY2021	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-600000	usd
CY2020	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-200000	usd
CY2022	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-100000	usd
CY2021	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-200000	usd
CY2020	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-200000	usd
CY2022	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	400000	usd
CY2021	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	0	usd
CY2020	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	-1000000.0	usd
CY2022	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	800000	usd
CY2021	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	2000000.0	usd
CY2020	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	2400000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	-8700000	usd
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.021
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.003
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.035
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.030
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.018
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.014
CY2022Q4	us-gaap	Defined Benefit Plan Expected Future Employer Contributions Next Fiscal Year DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear	1600000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	9000000.0	usd
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	5900000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	300000	usd
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	1300000	usd
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	-4600000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths	1800000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Two DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo	1800000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Three DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree	2000000.0	usd
CY2022Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Four DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour	1900000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Five DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive	2100000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Five Fiscal Years Thereafter DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter	27600000	usd
CY2022Q4	ebs	Defined Benefit Plan Expected Future Benefit Payment DefinedBenefitPlanExpectedFutureBenefitPayment	37200000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	8800000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	8900000	usd
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	6600000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	132800000	usd
CY2022	us-gaap	Longterm Purchase Commitment Period LongtermPurchaseCommitmentPeriod	P5Y
CY2022Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	125700000	usd
CY2022	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	199600000	usd
CY2021	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	110700000	usd
CY2020	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	108000000	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022	us-gaap	Revenues Revenues	1120900000	usd
CY2021	us-gaap	Revenues Revenues	1792700000	usd
CY2020	us-gaap	Revenues Revenues	1555400000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	693700000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	757500000	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	524000000.0	usd
CY2022	us-gaap	Gross Profit GrossProfit	385800000	usd
CY2021	us-gaap	Gross Profit GrossProfit	901000000.0	usd
CY2020	us-gaap	Gross Profit GrossProfit	916300000	usd
CY2022	ebs	Adjusted Gross Margin AdjustedGrossMargin	439800000	usd
CY2021	ebs	Adjusted Gross Margin AdjustedGrossMargin	903900000	usd
CY2020	ebs	Adjusted Gross Margin AdjustedGrossMargin	948000000.0	usd
CY2022	ebs	Gross Profit Adjustments GrossProfitAdjustments	-54000000.0	usd
CY2021	ebs	Gross Profit Adjustments GrossProfitAdjustments	-2900000	usd
CY2020	ebs	Gross Profit Adjustments GrossProfitAdjustments	-31700000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	193000000.0	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	234000000.0	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	234500000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	340300000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	348400000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	303300000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	6700000	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	41700000	usd
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	59900000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	58500000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	59800000	usd
CY2022	us-gaap	Interest Expense InterestExpense	37300000	usd
CY2021	us-gaap	Interest Expense InterestExpense	34500000	usd
CY2020	us-gaap	Interest Expense InterestExpense	31300000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11700000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3700000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4700000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-221700000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	314400000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	407200000	usd
CY2022	us-gaap	Depreciation Depreciation	83400000	usd
CY2021	us-gaap	Depreciation Depreciation	62200000	usd
CY2020	us-gaap	Depreciation Depreciation	50100000	usd
CY2022	us-gaap	Revenues Revenues	1120900000	usd
CY2021	us-gaap	Revenues Revenues	1792700000	usd
CY2020	us-gaap	Revenues Revenues	1555400000	usd
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	826700000	usd
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	819600000	usd
CY2022	dei	Auditor Firm AuditorFirmId	42

Files In Submission

Name	View Source	Status
0001367644-23-000046-index-headers.html	Edgar Link	pending
0001367644-23-000046-index.html	Edgar Link	pending
0001367644-23-000046.txt	Edgar Link	pending
0001367644-23-000046-xbrl.zip	Edgar Link	pending
a311-kramercert123122.htm	Edgar Link	pending
a312-lindhalcert123122.htm	Edgar Link	pending
a321-kramercert123122.htm	Edgar Link	pending
a322-lindhalcert123122.htm	Edgar Link	pending
consentlimitedwaiverandt.htm	Edgar Link	pending
consentlimitedwaiverandt001.jpg	Edgar Link	pending
consentlimitedwaiverandt002.jpg	Edgar Link	pending
consentlimitedwaiverandt003.jpg	Edgar Link	pending
consentlimitedwaiverandt004.jpg	Edgar Link	pending
consentlimitedwaiverandt005.jpg	Edgar Link	pending
consentlimitedwaiverandt006.jpg	Edgar Link	pending
consentlimitedwaiverandt007.jpg	Edgar Link	pending
consentlimitedwaiverandt008.jpg	Edgar Link	pending
consentlimitedwaiverandt009.jpg	Edgar Link	pending
consentlimitedwaiverandt010.jpg	Edgar Link	pending
consentlimitedwaiverandt011.jpg	Edgar Link	pending
consentlimitedwaiverandt012.jpg	Edgar Link	pending
consentlimitedwaiverandt013.jpg	Edgar Link	pending
consentlimitedwaiverandt014.jpg	Edgar Link	pending
consentlimitedwaiverandt015.jpg	Edgar Link	pending
consentlimitedwaiverandt016.jpg	Edgar Link	pending
consentlimitedwaiverandt017.jpg	Edgar Link	pending
consentlimitedwaiverandt018.jpg	Edgar Link	pending
consentlimitedwaiverandt019.jpg	Edgar Link	pending
consentlimitedwaiverandt020.jpg	Edgar Link	pending
consentlimitedwaiverandt021.jpg	Edgar Link	pending
consentlimitedwaiverandt022.jpg	Edgar Link	pending
consentlimitedwaiverandt023.jpg	Edgar Link	pending
consentlimitedwaiverandt024.jpg	Edgar Link	pending
consentlimitedwaiverandt025.jpg	Edgar Link	pending
consentlimitedwaiverandt026.jpg	Edgar Link	pending
consentlimitedwaiverandt027.jpg	Edgar Link	pending
ebs-20221231.htm	Edgar Link	pending
ebs-20221231.xsd	Edgar Link	pending
ebs-20221231_g1.jpg	Edgar Link	pending
ebs-20221231_g2.jpg	Edgar Link	pending
ebsstockincentiveplan-ja.htm	Edgar Link	pending
ebsstockincentiveplan-ja001.jpg	Edgar Link	pending
ebsstockincentiveplan-ja002.jpg	Edgar Link	pending
ebsstockincentiveplan-ja003.jpg	Edgar Link	pending
ebsstockincentiveplan-ja004.jpg	Edgar Link	pending
ebsstockincentiveplan-ja005.jpg	Edgar Link	pending
ebsstockincentiveplan-ja006.jpg	Edgar Link	pending
ebsstockincentiveplan-ja007.jpg	Edgar Link	pending
ebsstockincentiveplan-ja008.jpg	Edgar Link	pending
ebsstockincentiveplan-ja009.jpg	Edgar Link	pending
ebsstockincentiveplan-ja010.jpg	Edgar Link	pending
ebsstockincentiveplan-ja011.jpg	Edgar Link	pending
ebsstockincentiveplan-ja012.jpg	Edgar Link	pending
ebsstockincentiveplan-ja013.jpg	Edgar Link	pending
ebsstockincentiveplan-ja014.jpg	Edgar Link	pending
ebsstockincentiveplan-ja015.jpg	Edgar Link	pending
ebsstockincentiveplan-ja016.jpg	Edgar Link	pending
ebsstockincentiveplan-ja017.jpg	Edgar Link	pending
ebsstockincentiveplan-ja018.jpg	Edgar Link	pending
ebsstockincentiveplan-ja019.jpg	Edgar Link	pending
ebs-20221231_pre.xml	Edgar Link	unprocessable
ebs-20221231_lab.xml	Edgar Link	unprocessable
ebs-20221231_htm.xml	Edgar Link	completed
exhibit23-eyconsent.htm	Edgar Link	pending
exhibit23-eyconsent001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
listofsubsidiariesasofde.htm	Edgar Link	pending
listofsubsidiariesasofde001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
purchaseandsaleagreement.htm	Edgar Link	pending
purchaseandsaleagreement001.jpg	Edgar Link	pending
purchaseandsaleagreement002.jpg	Edgar Link	pending
purchaseandsaleagreement003.jpg	Edgar Link	pending
purchaseandsaleagreement004.jpg	Edgar Link	pending
purchaseandsaleagreement005.jpg	Edgar Link	pending
purchaseandsaleagreement006.jpg	Edgar Link	pending
purchaseandsaleagreement007.jpg	Edgar Link	pending
purchaseandsaleagreement008.jpg	Edgar Link	pending
purchaseandsaleagreement009.jpg	Edgar Link	pending
purchaseandsaleagreement010.jpg	Edgar Link	pending
purchaseandsaleagreement011.jpg	Edgar Link	pending
purchaseandsaleagreement012.jpg	Edgar Link	pending
purchaseandsaleagreement013.jpg	Edgar Link	pending
purchaseandsaleagreement014.jpg	Edgar Link	pending
purchaseandsaleagreement015.jpg	Edgar Link	pending
purchaseandsaleagreement016.jpg	Edgar Link	pending
purchaseandsaleagreement017.jpg	Edgar Link	pending
purchaseandsaleagreement018.jpg	Edgar Link	pending
purchaseandsaleagreement019.jpg	Edgar Link	pending
purchaseandsaleagreement020.jpg	Edgar Link	pending
purchaseandsaleagreement021.jpg	Edgar Link	pending
purchaseandsaleagreement022.jpg	Edgar Link	pending
purchaseandsaleagreement023.jpg	Edgar Link	pending
purchaseandsaleagreement024.jpg	Edgar Link	pending
purchaseandsaleagreement025.jpg	Edgar Link	pending
purchaseandsaleagreement026.jpg	Edgar Link	pending
purchaseandsaleagreement027.jpg	Edgar Link	pending
purchaseandsaleagreement028.jpg	Edgar Link	pending
purchaseandsaleagreement029.jpg	Edgar Link	pending
purchaseandsaleagreement030.jpg	Edgar Link	pending
purchaseandsaleagreement031.jpg	Edgar Link	pending
purchaseandsaleagreement032.jpg	Edgar Link	pending
purchaseandsaleagreement033.jpg	Edgar Link	pending
purchaseandsaleagreement034.jpg	Edgar Link	pending
purchaseandsaleagreement035.jpg	Edgar Link	pending
purchaseandsaleagreement036.jpg	Edgar Link	pending
purchaseandsaleagreement037.jpg	Edgar Link	pending
purchaseandsaleagreement038.jpg	Edgar Link	pending
purchaseandsaleagreement039.jpg	Edgar Link	pending
purchaseandsaleagreement040.jpg	Edgar Link	pending
purchaseandsaleagreement041.jpg	Edgar Link	pending
purchaseandsaleagreement042.jpg	Edgar Link	pending
purchaseandsaleagreement043.jpg	Edgar Link	pending
purchaseandsaleagreement044.jpg	Edgar Link	pending
purchaseandsaleagreement045.jpg	Edgar Link	pending
purchaseandsaleagreement046.jpg	Edgar Link	pending
purchaseandsaleagreement047.jpg	Edgar Link	pending
purchaseandsaleagreement048.jpg	Edgar Link	pending
purchaseandsaleagreement049.jpg	Edgar Link	pending
purchaseandsaleagreement050.jpg	Edgar Link	pending
purchaseandsaleagreement051.jpg	Edgar Link	pending
purchaseandsaleagreement052.jpg	Edgar Link	pending
purchaseandsaleagreement053.jpg	Edgar Link	pending
purchaseandsaleagreement054.jpg	Edgar Link	pending
purchaseandsaleagreement055.jpg	Edgar Link	pending
purchaseandsaleagreement056.jpg	Edgar Link	pending
purchaseandsaleagreement057.jpg	Edgar Link	pending
purchaseandsaleagreement058.jpg	Edgar Link	pending
purchaseandsaleagreement059.jpg	Edgar Link	pending
purchaseandsaleagreement060.jpg	Edgar Link	pending
purchaseandsaleagreement061.jpg	Edgar Link	pending
purchaseandsaleagreement062.jpg	Edgar Link	pending
purchaseandsaleagreement063.jpg	Edgar Link	pending
purchaseandsaleagreement064.jpg	Edgar Link	pending
purchaseandsaleagreement065.jpg	Edgar Link	pending
purchaseandsaleagreement066.jpg	Edgar Link	pending
purchaseandsaleagreement067.jpg	Edgar Link	pending
purchaseandsaleagreement068.jpg	Edgar Link	pending
purchaseandsaleagreement069.jpg	Edgar Link	pending
purchaseandsaleagreement070.jpg	Edgar Link	pending
purchaseandsaleagreement071.jpg	Edgar Link	pending
purchaseandsaleagreement072.jpg	Edgar Link	pending
purchaseandsaleagreement073.jpg	Edgar Link	pending
purchaseandsaleagreement074.jpg	Edgar Link	pending
purchaseandsaleagreement075.jpg	Edgar Link	pending
purchaseandsaleagreement076.jpg	Edgar Link	pending
purchaseandsaleagreement077.jpg	Edgar Link	pending
purchaseandsaleagreement078.jpg	Edgar Link	pending
purchaseandsaleagreement079.jpg	Edgar Link	pending
purchaseandsaleagreement080.jpg	Edgar Link	pending
purchaseandsaleagreement081.jpg	Edgar Link	pending
purchaseandsaleagreement082.jpg	Edgar Link	pending
purchaseandsaleagreement083.jpg	Edgar Link	pending
purchaseandsaleagreement084.jpg	Edgar Link	pending
purchaseandsaleagreement085.jpg	Edgar Link	pending
purchaseandsaleagreement086.jpg	Edgar Link	pending
purchaseandsaleagreement087.jpg	Edgar Link	pending
purchaseandsaleagreement088.jpg	Edgar Link	pending
purchaseandsaleagreement089.jpg	Edgar Link	pending
purchaseandsaleagreement090.jpg	Edgar Link	pending
purchaseandsaleagreement091.jpg	Edgar Link	pending
purchaseandsaleagreement092.jpg	Edgar Link	pending
purchaseandsaleagreement093.jpg	Edgar Link	pending
purchaseandsaleagreement094.jpg	Edgar Link	pending
purchaseandsaleagreement095.jpg	Edgar Link	pending
purchaseandsaleagreement096.jpg	Edgar Link	pending
purchaseandsaleagreement097.jpg	Edgar Link	pending
purchaseandsaleagreement098.jpg	Edgar Link	pending
purchaseandsaleagreement099.jpg	Edgar Link	pending
purchaseandsaleagreement100.jpg	Edgar Link	pending
purchaseandsaleagreement101.jpg	Edgar Link	pending
purchaseandsaleagreement102.jpg	Edgar Link	pending
purchaseandsaleagreement103.jpg	Edgar Link	pending
purchaseandsaleagreement104.jpg	Edgar Link	pending
purchaseandsaleagreement105.jpg	Edgar Link	pending
purchaseandsaleagreement106.jpg	Edgar Link	pending
purchaseandsaleagreement107.jpg	Edgar Link	pending
purchaseandsaleagreement108.jpg	Edgar Link	pending
purchaseandsaleagreement109.jpg	Edgar Link	pending
purchaseandsaleagreement110.jpg	Edgar Link	pending
purchaseandsaleagreement111.jpg	Edgar Link	pending
purchaseandsaleagreement112.jpg	Edgar Link	pending
purchaseandsaleagreement113.jpg	Edgar Link	pending
purchaseandsaleagreement114.jpg	Edgar Link	pending
purchaseandsaleagreement115.jpg	Edgar Link	pending
purchaseandsaleagreement116.jpg	Edgar Link	pending
purchaseandsaleagreement117.jpg	Edgar Link	pending
purchaseandsaleagreement118.jpg	Edgar Link	pending
purchaseandsaleagreement119.jpg	Edgar Link	pending
purchaseandsaleagreement120.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ebs-20221231_cal.xml	Edgar Link	unprocessable
ebs-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EBS
Emergent BioSolutions Inc. Stock $ebs

2023 Q1 Form 10-K Financial Statement

#000136764423000046 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EBS Emergent BioSolutions Inc. Stock $ebs

2023 Q1 Form 10-K Financial Statement

#000136764423000046 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EBS
Emergent BioSolutions Inc. Stock $ebs